Capital World Investors Allakos Inc. Transaction History

Capital World Investors

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.55 - $111.89 $56.6 Million - $740 Million	-6,614,358 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $3.99 Million - $5.76 Million	52,126 Added 0.79%	6,614,358 $700 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $4.73 Million - $6.32 Million	55,403 Added 0.85%	6,562,232 $560 Million
Q1 2021 May 14, 2021	BUY	$109.73 - $153.66 $8.25 Million - $11.6 Million	75,190 Added 1.17%	6,506,829 $747 Million
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $50.7 Million - $97.1 Million	636,979 Added 10.99%	6,431,639 $900 Million
Q3 2020 Nov 13, 2020	BUY	$66.43 - $90.99 $2.06 Million - $2.83 Million	31,062 Added 0.54%	5,794,660 $472 Million
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $24.1 Million - $44.1 Million	546,407 Added 10.47%	5,763,598 $414 Million
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $51.1 Million - $107 Million	1,149,691 Added 28.27%	5,217,191 $232 Million
Q4 2019 Feb 18, 2020	BUY	$66.49 - $137.73 $38.1 Million - $78.9 Million	572,648 Added 16.39%	4,067,500 $388 Million
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $39.3 Million - $114 Million	1,267,405 Added 56.9%	3,494,852 $275 Million
Q2 2019 Aug 14, 2019	BUY	$36.0 - $44.73 $80.2 Million - $99.6 Million	2,227,447 New	2,227,447 $96.5 Million

68.8M

20.9K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $20.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.